90 related articles for article (PubMed ID: 32360170)
1. A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial.
Shore ND; Pieczonka CM; Henderson RJ; Bailen JL; Saltzstein DR; Concepcion RS; Beebe-Dimmer JL; Ruterbusch JJ; Le TH; Levin RA; Wissmueller S; Prah P; Borotkanics R; Paivanas TA; van Breda A; Campbell DH; Walsh BJ
Urol Oncol; 2020 Aug; 38(8):683.e1-683.e10. PubMed ID: 32360170
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of the MiCheck test for aggressive prostate cancer.
Shore ND; Pieczonka CM; Henderson RJ; Bailen JL; Saltzstein DR; Concepcion RS; Beebe-Dimmer JL; Ruterbusch JJ; Levin RA; Wissmueller S; Le TH; Gillatt D; Chan DW; Campbell DH; Walsh BJ
Urol Oncol; 2020 Aug; 38(8):683.e11-683.e18. PubMed ID: 32305266
[TBL] [Abstract][Full Text] [Related]
3. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
4. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.
Sokoll LJ; Sanda MG; Feng Z; Kagan J; Mizrahi IA; Broyles DL; Partin AW; Srivastava S; Thompson IM; Wei JT; Zhang Z; Chan DW
Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1193-200. PubMed ID: 20447916
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
Morote J; Celma A; Planas J; Placer J; Ferrer R; de Torres I; Pacciuci R; Olivan M
Actas Urol Esp; 2016; 40(6):378-85. PubMed ID: 26923032
[TBL] [Abstract][Full Text] [Related]
7. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
Furuya K; Kawahara T; Narahara M; Tokita T; Fukui S; Imano M; Mitome T; Ito Y; Izumi K; Osaka K; Yokomizo Y; Hayashi N; Hasumi H; Nawata S; Kawano T; Yao M; Uemura H
Scand J Urol; 2017 Aug; 51(4):251-257. PubMed ID: 28351193
[TBL] [Abstract][Full Text] [Related]
8. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
9. Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan.
Fan YH; Pan PH; Lin TP; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS
J Chin Med Assoc; 2019 Oct; 82(10):772-777. PubMed ID: 31356566
[TBL] [Abstract][Full Text] [Related]
10. Preoperative prostate health index and %p2PSA as the significant biomarkers of postoperative pathological outcomes of prostate cancer in Korean males: A prospective multi-institutional study.
Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park JY; Shin TY; Kim JH
Investig Clin Urol; 2020 Jan; 61(1):42-50. PubMed ID: 31942462
[TBL] [Abstract][Full Text] [Related]
11. Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study.
Klein EA; Partin A; Lotan Y; Baniel J; Dineen M; Hafron J; Manickam K; Pliskin M; Wagner M; Kestranek A; Stovsky M
Urol Oncol; 2022 Sep; 40(9):408.e9-408.e18. PubMed ID: 35840465
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range.
Vukovic I; Djordjevic D; Bojanic N; Babic U; Soldatovic I
Int Braz J Urol; 2017; 43(1):48-56. PubMed ID: 28124526
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].
Lamy PJ; Montels F; Tosi D; Leizour B; Bascoul-Mollevi C; Castan F; Roques S; Nielloud F; Rebillard X
Ann Biol Clin (Paris); 2013; 71(5):537-44. PubMed ID: 24113439
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
15. Prostate Health Index density improves detection of clinically significant prostate cancer.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
[TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
[TBL] [Abstract][Full Text] [Related]
17. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
Sokoll LJ; Mangold LA; Partin AW; Epstein JI; Bruzek DJ; Dunn W; Mohr P; Wallerson G; Chan DW
Urology; 2002 Oct; 60(4 Suppl 1):18-23. PubMed ID: 12384158
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.
Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park CH; Park JY; Shin TY; Suh IB; Kim JH
J Korean Med Sci; 2018 Mar; 33(11):e94. PubMed ID: 29495138
[TBL] [Abstract][Full Text] [Related]
19. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations.
Veltri RW; Miller MC
Urology; 1999 Apr; 53(4):736-45. PubMed ID: 10197849
[TBL] [Abstract][Full Text] [Related]
20. The prostate health index selectively identifies clinically significant prostate cancer.
Loeb S; Sanda MG; Broyles DL; Shin SS; Bangma CH; Wei JT; Partin AW; Klee GG; Slawin KM; Marks LS; van Schaik RH; Chan DW; Sokoll LJ; Cruz AB; Mizrahi IA; Catalona WJ
J Urol; 2015 Apr; 193(4):1163-9. PubMed ID: 25463993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
